VRVertex Pharmaceuticals VRTX · NASDAQ
$514.65 +2.53% (+$12.70)
- Market cap
- $127.2B
- Enterprise value
- $123.1B
- P/E
- 28.9x
- Forward P/E
- 28.1x
- PEG
- -
- P/S
- 10.1x
- P/FCF
- 33.5x
- EV/EBITDA
- 22.6x
- ROIC
- 17.3%
- Gross margin
- 86.0%
- Net margin
- 34.9%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -0.8x
- Beta
- 0.32
- Free float
- 99.8%
About the company
Vertex Pharmaceuticals (VRTX) is a leading biopharmaceutical company specializing in the development of drugs for the treatment of rare and severe diseases. Their primary focus is on the development of innovative therapies for patients with cystic fibrosis, a genetic disorder affecting the respiratory and digestive systems. Vertex Pharmaceuticals is at the forefront of gene therapy and molecular-based treatments. Vertex Pharmaceuticals stock is suitable for investors interested in the pharmaceutical sector and investments in the treatment of rare diseases. Add Vertex Pharmaceuticals stock to your watchlist on Bulios and be the first to receive updates on new medical breakthroughs and the development of therapies from this prominent company.
Sector
Healthcare
Industry
Biotechnology
CEO
Reshma Kewalramani
Employees
6,400
Headquarters
Boston
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number